Abstract PHB05: Mechanism-based computational models to study interplay between EGFR inhibitors and KRAS mutants
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.camodels2020-phb05
Abstract: An early genotype-to-phenotype relationship in cancer personalized medicine was that KRAS mutations confer resistance to EGFR inhibitors in colorectal cancer. Confusingly, phase 3 clinical trials found that patients with the KRAS G13D mutation were an… read more here.
Keywords: egfr inhibitors; cancer; computational models; kras g13d ... See more keywords
Abstract B03: Biologic and biochemical interactions of NF1 GAP on KRAS G13x mutations
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras18-b03
Abstract: KRAS mutations are common among 30% of cancers and promote tumor growth by constitutively activating the MAPK pathway independent of mitogenic stimuli. KRAS mutations at codons 12, 13, or 61 stabilize the KRAS-GTP complex by… read more here.
Keywords: gap; biologic biochemical; nf1 p120; kras g13d ... See more keywords
CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14215449
Abstract: Simple Summary BRAF inhibitor drug resistance has been a long-time challenge in the treatment of melanoma with BRAF V600E mutation. This study employed the CRISPR/Cas9 technology to generate three isogenic A375 melanoma cell lines with… read more here.
Keywords: cell; kras g13d; braf; inhibitor ... See more keywords
Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms21176037
Abstract: The now clinically-used anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have demonstrated significant efficacy only in patients with metastatic colorectal cancer (mCRC), with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS). However, no effective treatments… read more here.
Keywords: egfr monoclonal; colorectal cancer; antibody; anti egfr ... See more keywords